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Abstract: The novel zinc(II) µ-oxo-bridged-dimeric complex [Zn2(µ-O)2(BMIP)2] (BMIP = 1,3-bis(5-
methoxy-1-methyl-1H-indol-3-yl)propane-1,3-dione), 1, was synthetized and fully characterized.
The spectral data indicate a zincoxane molecular structure, with the BMIP ligand coordinating in
its neutral form via its oxygen atoms. Structural changes in 1 in dimethylsulfoxide (DMSO) were
evidenced by means of spectroscopic techniques including infrared absorption and nuclear magnetic
resonance, showing DMSO entrance in the coordination sphere of the metal ion. The resulting
complex [Zn2(µ-O)2(BMIP)2(DMSO)], 2, readily reacts in the presence of N-methyl-imidazole (NMI),
a liquid-phase nucleoside mimic, to form [Zn2(µ-O)2(BMIP)2(NMI)], 3, through DMSO displacement.
The three complexes show high thermal stability, demonstrating that 1 has high affinity for hard
nucleophiles. Finally, with the aim of probing the suitability of this system as model scaffold for new
potential anticancer metallodrugs, the interactions of 1 with calf thymus DNA were investigated
in vitro in pseudo-physiological environment through UV-Vis absorption and fluorescence emis-
sion spectroscopy, as well as time-resolved fluorescence studies. The latter analyses revealed that
[Zn2(µ-O)2(BMIP)2(DMSO)] binds to DNA with high affinity upon DMSO displacement, opening
new perspectives for the development of optimized drug substances.
Keywords: zinc(II) complexes; indoles; β-diketone; DNA ligand; metallodrug; DNA-targeted
chemotherapy
1. Introduction
Since the anticancer properties of cisplatin were first discovered by Rosenberg in
1965 [1], many efforts have been focused on both finding more effective metallodrugs
and reducing the severe side effects typical of the parent compound [2–5]. In particular,
β-diketone-based metal complexes are constantly catching interest [6,7] due to
β-dicarbonyls’ structural simplicity and, in case of, e.g., curcuminoid compounds, in-
trinsic biological properties and natural availability [8]. For instance, Lippard reported
benzoylacetonate platinum(II) complexes to preserve antitumor activity, in some cases even
at lower doses than uncomplexed cisplatin [9]. Among non-platinum based compounds,
in 1995, Hanauske and coworkers introduced budotitane as the first titanium(IV) drug
for cancer treatment [10]. Other cytotoxic β-dicarbonyls exploit the presence of RuII [11],
CoII [12], CuII [13,14], NiII [15,16] and oxovanadium(IV) [17].
Among cheap and low-toxicity metal ions of the d-block, zinc(II) is one of the most
abundant ones naturally present in the human body [18,19] and plays key roles in cell
metabolism [20,21]. Recently, many ZnII complexes with good DNA-binding properties were
synthetized, exploiting different types of bidentate ligands such as bis(thiosemicarbazone) [22],
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isoeuxanthone [23], 5,7-dihalo-8-substituted quinolones [24], oxolinic acid [25] and Hpyra-
mol [26]. However, only few examples of cytotoxic ZnII β-diketone-based metallodrugs are
reported in the literature, containing either acetylacetone [27], 2-thenoyltrifluoroacetone [28]
or curcuminoid fragments [29–31].
Indole derivatives have tremendous relevance for their biological importance [32–34]
and they are subjected to extensive research for their anticancer properties [35–37]. In
2010, Cirrincione and coworkers provided new bis(indol-3-yl)propane-1,3-dione molecules
as intermediates to achieve nortopsentin analogues with antitumor potential [38]. Given
our general interest in indole chemistry [39–41] and inspired by Cirrincione’s work, we
present in this paper the synthesis and characterization of a novel ZnII complex, [Zn2(µ-
O)2(BMIP)2], 1, (Scheme 1). A deep analysis of the molecular structure of 1 has been
carried out, revealing a zincoxane core which binds the BMIP ligand in neutral form.
Compound 1 shows good affinity for hard nucleophiles, as it can readily expand its
coordination sphere when dissolved in DMSO, forming the [Zn2(µ-O)2(BMIP)2(DMSO)]
species, 2. Moreover, the DMSO ligand can be easily displaced by N-methyl-imidazole
(NMI), a common nucleoside mimic, leading to the formation of [Zn2(µ-O)2(BMIP)2(NMI)],
3. The three compounds show high thermal stability. Finally, successful DNA coordination
tests in pseudo-physiological buffer solution suggest that 1 can be regarded as a scaffold
compound for a new family of potential anticancer drugs.
2. Results and Discussion
2.1. Synthesis
Synthesis of the BMIP ligand was accomplished by acylation of the electron-rich
5-methoxy-N-methyl-indole with malonyl dichloride [38]. Compound 1 was afforded by
reaction of BMIP with zinc(II) perchlorate in basic conditions (Scheme 1). Further details
are given in the Supplementary Materials section.
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2.2. Spectroscopic and Structural Studies
2.2.1. NMR Spectroscopy
As the 1H-NMR spectrum of 1 in CD2Cl2 shows a symmetrical aromatic pattern (see
Supplementary Materials Figure S1), BMIP metal chelation via the carbonyl oxygens can
be assumed. Concerning the upfield region, the signals for the indole N-Me and the 5-
methoxy groups were found overlapped at 3.76 ppm, whilst in free BMIP they are observed
as distinct singlets at 3.75 and 3.77 ppm, respectively. More interestingly, the 1H-NMR
spectrum of 1 shows a signal at 4.32 ppm, similar to that found for the β-dicarbonyl CH2
in the free ligand, the associated integral being compatible with two protons. This suggests
that BMIP mainly coordinates via its neutral keto form, rather than its enolate (Scheme 2).
This is supported also by the 13C-NMR spectrum (Supplementary Materials Figure S2),
clearly evidencing not only the β-dicarbonyl CH2 at 55 ppm, but even the ketone carbon
signal at 188 ppm. Many examples of chelating neutral diketone complexes are already
documented in the literature, mainly containing acetylacetone [42–44]. However, if BMIP
is present as neutral ligand, an anionic charge compensator for ZnII must be present.
Lewinski recently reported that a characteristic zincoxane Zn-O-Zn bridged structure is
Pharmaceuticals 2021, 14, 760 3 of 17
quite common in zinc(II) coordination chemistry [45]. In particular, treatment of zinc(II)
acetylacetonate in refluxing polar solvents leads to formation of Zn-O clusters [46].
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The stoichiometry of complex 1, determined by assessing its molecular weight with
high-resolution mass spectrometry (HRMS) and elemental analysis, points to the formation
of a ZnII dinuclear complex, formally viewed as two [Zn(BMIP)]2+ units with the zinc(II)
centers bridged by two µ2-O2− anions (Scheme 1). The presence of µ2-O2− is required to
neutralize the positive charge of the [Zn(BMIP)]2+ unit. The molecular structure of 1 may
then be formally considered as a dimeric zincoxane stabilized by the organic ligand. In
addition, the presence in the 1H-NMR spectrum of 1 of side peaks in the aromatic region
at 7.70 ppm, 7.68 ppm, 7.22 ppm and 6.88 ppm, and of the characteristic olefin proton
at 6.50 ppm (see Figure 1) reveals the coexistence of the enolic neutral form (Scheme 2)
together with the prevalent diketo one. The presence of the enol tautomer in neutral
coordinated β-dicarbonyls is already documented in the literature [42,43].
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2.2.2. IR Spectroscopy
The FT-IR analysis of compound 1 (Table 1 and Supplementary Materials Figure S3)
reveals that the C=O stretching band is located at 1520 cm−1, strongly red-shifted compared
to the homologous vibration at 1618 cm−1 detected for the BMIP free ligand. This marked
difference is a good evidence of strong coordination of the metal ion through the β-diketone
oxyg n atom [47]. Furthermor , two additional bands lacking in the ligand spectrum
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appear in the low frequency region at 507 cm−1, which may be attributed to Zn-OBMIP
vibrations [48].
Table 1. IR frequencies (cm−1) of BMIP, 1, 2 and 3.











ligand 2939 1620 1210
1 3020 2950 1520 1260 507
2 3020 2950 1520 1260 1031 961 510 435
3 3020 2950 1520 1260 1421 1285 518
2.2.3. Electronic-State Transition Spectroscopy
UV-Vis Absorption in Organic Solvents
In order to further investigate the keto-enol tautomerism of 1 in different environ-
ments, UV-Vis absorption spectroscopy experiments were undertaken. Namely, the UV-Vis
absorption spectra of 1 were recorded in a panel of organic solvents and in water. Unfor-
tunately, due to the low solubility of 1 in most environments, only a limited number of
solvents could be probed, namely: dichloromethane (DCM), as a benchmark of slightly
polar poorly hydrogen-bonding solvent; DMSO and dimethylformamide (DMF), as bench-
marks of highly polar, H-bond accepting solvent; and ethanol (EtOH), as a paradigm of
protic solvent. In EtOH, 1 is only slightly soluble (saturation is reached in the micromolar
concentration range). Thus, filtration of the solution over paper was necessary to obtain
clear (i.e.,: non-scattering) samples. The absorption spectra are plotted in Figure 2. Due
to the high absorption of DMSO and DMF in the UVB spectral region, our analysis has
focused on the 270–650 nm range. The spectra acquired in any of the tested solvents exhibit
two distinct absorption peaks, one around λabs,1 ≈ 310 nm and another at λabs,2 ≈ 395 nm.
The exact positions of the absorption peaks are reported in Table 2.
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The peaks positions and bands’ line-shapes are only slightly affected by the solvent
properties. Conversely, the relative intensity of the two bands dramatically changes, as
seen in Table 2, fourth column, where the values of f1 = Abs(310 nm)/[Abs(310 nm) +
Abs(395 nm)] are reported.
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Relying on previous experiences [49,50] as well as literature data [51] on other
β-diketones, we attributed the 310 nm peaked band to the absorption of the BMIP lig-
ands in the diketo tautomer, and the 395 nm peaked one to the absorption of those in the
enol form. According to this interpretation, the coexistence of two peaks in all the solvents
would support the picture offered by NMR, suggesting that both the diketo and the enol
tautomers are able to chelate zinc(II) ions with comparable efficacy, and that the keto-enolic
equilibrium is primarily dictated by solute–solvent interactions, rather than complexation.
Table 2. UV-Vis absorption properties of 1 in different solvents: peak wavelength of the first
absorption band, λabs,1, and of the second absorption band, λabs,2; relative intensity of the first
absorption peak, f1; fraction of diketo tautomers according to NMR, fDiketo,NMR; average molar
extinction coefficient, <ε> (see text for details).
Solvent λabs,1 (nm) λabs,2 (nm) f1 fDiketo,NMR <ε> (M−1cm−1)
DCM 313 (35,000) 392 (32,900) 0.79 0.85 34,600
DMF 302 392 0.57 44,100
DMSO 309 (41,500) 393 (43,000) 0.45 0.46 42,400
EtOH 311 397 0.76 –
The bands’ attribution is corroborated by comparison of the relative peak absorbance
f1, retrieved from the UV-Vis spectra, with the relative integral of the signals at 7.16 ppm
and 7.22 ppm, characteristic of the diketo and enol tautomers, respectively, in the 1H-NMR
spectra in deuterated DCM and DMSO (see fifth column of Table 2). Unfortunately, the
acquisition of NMR spectra in EtOH was prevented by the scarce solubility of 1 in this
solvent, while we did not investigate the equilibrium in deuterated DMF due to shortage
of this solvent. However, the almost perfect matching of the relative absorbance with
the fractional concentration values in both the solvents used for double-blind analysis
by means of UV-Vis and NMR spectroscopy (Table 2, columns 4 and 5) implies that, at
least in DCM and DMSO, the molar extinction coefficient is very similar at the diketo
and keto-enol absorption peak. Indeed, estimation of this spectroscopic parameter is
feasible on solutions in which the total concentration of 1 is predetermined by weight (see
Materials and Methods for details). In such specimens, the fractional concentrations of
diketo and enol tautomers established by NMR can be adopted to calculate the absolute
diketo and enol concentration values. The resulting molar extinction coefficients (reported
in parenthesis beneath the peak wavelengths of the pertaining absorption peaks in the
second and third column of Table 2) differ by few percent. Under the assumption that this
similarity holds true also in the other solvents, the relative absorbance values reported in
the fourth column of Table 2 constitute good estimates of the fractional concentration of
diketo tautomer also in DMF, and the average molar extinction coefficient can be calculated
(see last column in Table 2). Due to the necessity of preliminarily filtering the EtOH solution,
it was impossible to derive the molar extinction coefficient value in this solvent, instead.
Steady-State Fluorescence in Organic Solvents
The fluorescence emission spectra of 1 in the above-investigated solvents were recorded
upon excitation at both the enol and the diketo absorption peak. They are plotted
in Figure 3, panels (a) and (b), respectively. Excitation at the ≈395 nm (enol) peak re-
sults in an emission peaked at around 425 nm, with the exception of the notably red-shifted
spectrum measured in EtOH (λmax ≈ 450 nm). The exact values of the maximum emission
wavelength in the different solvents are listed in Table 3.
A similar behavior (red-shifted fluorescence in alcohols) was observed for several cur-
cuminoids, and ascribed to tautomerism between the open cis- and trans-enol
species [49,50,52–57]. The quantum yield of 1 is generally low (see the values reported
in Table 3). In spite of this, excitation at the ≈310 nm (diketo) peak results in spectra
dominated by out-of-peak excited emission of the enol tautomers, while the emission of
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the diketo ones builds up a secondary band peaked at ≈350 nm, suggesting an even lower
quantum yield for the latter tautomers.
This attribution is corroborated by the fluorescence excitation spectra recorded with
λobs = 425 nm and 350 nm, which peak at ≈395 nm and around 300 nm, respectively (see
Supplementary Materials Figure S4). The only exceptions to this rule are the excitation
spectrum recorded with λobs = 425 nm in DCM, which has a maximum at 326 nm due to
the high prevalence of the diketo tautomers in this solvent, and the excitation spectrum
with λobs = 350 nm in DMF, which peaks at 280 nm, with a marked shoulder above 300 nm.
Again by analogy with previously reported studies on curcumin analogues [49,50], this
might indicate a non-trivial cis-/trans-tautomerism between the diketo tautomers in this
solvent. Subtraction of out-of-peak excited fluorescence by the enolic species allowed
to reconstruct the spectral features of the diketo emission (see Supplementary Materials
Figure S5).
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Table 3. Fluorescence properties of 1 in selected solvents: peak fluorescence emission wavelengths
upon excitation at the enol, λemi,enol, and diketo, λemi,diketo, absorption peak; peak fluorescence
excitation wavelengths with fluorescence recording at the enol emission peak, λexc,enol, and at 350 nm,
λexc,diketo; fluorescence quantum yield of the enol tautomers, Φfluo,enol.
Solvent λemi,enol (nm) λemi,diketo (nm) † λexc,enol (nm) λexc,diketo (nm) Φfluo,enol
DCM 426 403 326 (398) 315 0.06
DMF 424 405 400 (325) 280 (309) 0.08
DMSO 428 403 400, 408 (322) 293, 304 0.12
EtOH 447 413 401 (325) 292 0.20
† reconstructed by subtraction of the out-of-peak excited fluorescence of the enol tautomers, see text for detailed
procedure.
Spectroscopic Properties in Aqueous Environment
With the final goal to characterize the binding affinity of 1 for DNA in pseudo-
physiological environment, a spectroscopic characterization of 1 in aqueous solution
(namely phosphate buffer at pH 7.4 and 10 mM ionic strength) was undertaken. These
investigations were hampered by the very low solubility of 1 in water. The low ionic
strength adopted was indeed necessary in order to prevent ready precipitation of the
compound. Nonetheless, in order to attain a clear solution, preliminary solubilization in
DMSO followed by re-equilibration in buffer was necessary. In Figure 4a, selected spectra
are plotted of a time-lapse experiment in which 50 µL of a 880 µM concentrated stock of 1
in DMSO are added to 2.95 mL of buffer. Readily after addition, the absorption spectrum
(red curve) is very similar t that detected for a solution of 1 in pure DMSO (see Figure 2
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for comparison). However, as solvent rearrangement takes place, DMSO is removed from
the microenvironment of the compound and the latter is hydrated, the absorption peak
at 390 nm characteristic of the enol tautomers progressively decreases in intensity at the
advantage of a peak at 320 nm, which we ascribe to the absorption of hydrated diketo
tautomers. Concomitantly, the peak at 310 nm typical of the diketo tautomers in DMSO
also reduces its intensity. As shown in Figure 4, panel (b), where the absorbance values at
320 nm and 393 nm are plotted as a function of time, within 5 h after addition of the stock,
the spectrum, plotted in black in Figure 4a, appears constituted by a single band peaked at
320 nm. This observation agrees with previous reports on the superior water solubility of
the diketo with respect to the enol tautomers of synthetic curcuminoids [51]. Nonetheless,
at length even the diketo tautomer tends to aggregate and precipitate, as denounced by
progressive reduction in the absorbance at 320 nm.
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for details.
For this reason, during the measurements in aqueous environment reported hereafter,
where not otherwise stated, the samples were kept under stirring. Upon excitation in
correspondence to the 320 nm peak of solutions kept under stirring overnight to achieve
completion of solvent rearrangement, a fluorescence peak at 460 nm was detected (see
Figure 5 for the emission spectrum). The quantum yield was measured to be 0.02.
Binding to DNA
The same measurements performed in aqueous environment were repeated upon
addition of 50 µL of the same stock of 1 in DMSO to 2.95 mL of buffer in which 150 µM
calf thymus DNA had been preliminarily dissolved. The solvent rearrangement dynamics
resulted to be minimally affect d by the presence of DNA. Howeve , fter complete h dra-
tion, the aggregation/precipita ion dynamics take place with significantly slower kinetics
(see Figure 4b, dotted li es). We interpret this phenom non as due to bi ding of 1 to DNA
and consequent slower precipitation of the complex.
The absorption spectral line-shape is slightly blue shifted to ≈315 nm. However, a
sizeable hyperchromicity is observed, as shown in Figure 4a (gray line). Moreover, a very
faint band appears peaking around 400 nm, i.e., in the absorption region typical of the enol
tautomers. A similar behavior also pertains to aqueous solutions with and without DNA
in which 1 is added upon preliminary solubilization in DMF, as shown in Supplementary
Materials Figure S6a. In the latter case, absorption in the enol band is not detected.
The most striking effect of DNA addition concerns fluorescence emission. Namely, the
fluorescence intensity is reduced to a barely detectable signal, see Figure 5, gray line, and
Pharmaceuticals 2021, 14, 760 8 of 17
Figure S6b, for the spectrum detected on the samples added with 1 dissolved in DMSO
and DMF, respectively.
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Accordingly, fluorescence quenching was assumed as a binding indicator and titration
was attempted with the aim of estimating the apparent binding constant of the reaction.
The details on samples preparation are provided in the Materials and Methods section.
The binding isotherms (i.e., graphs of fluorescence at 460 nm plotted as a function of
DNA concentration) obtained starting from 1 dissolved in DMSO and DMF are shown
in Figure 6, together with the pertaining best-fitting curves according to the independent
binding site model [58,59], i.e., using the following equation:




nKdiss + D + CDNA −
√
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the ligand in water, equal aliquots of concentrated stocks in organic solvents miscible with water were added to aqueous
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was 20 µM; in panel (b), DMF was used and the ligand was added to a final concentration of 15 µM. In both the experiments,
the volume-to-volume concentration of organic solvent in phosphate buffer was 1:150.
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In Equation (1) F(CDNA) is the fluorescence measured for a solution at D concentration
of 1 and CDNA concentration of DNA base pairs. D was kept constant to the values of
20 µM and 15 µM for the titrations starting from the DMSO and DMF stocks, respectively,
and fixed accordingly during the fit. F0 represents the fluorescence of the free dye, δFxD
the difference in fluorescence of the dye when totally bound to DNA with respect to F0.
The parameters descriptive of the binding affinity are the dissociation constant, Kdiss, and
the number of molecules of 1 reacting per DNA base pair in conditions of full binding
sites saturation, n (i.e., the inverse of the number of bases involved in the binding of a
single ligand molecule, the so-called binding length). The detailed fitting parameters are
reported in Table 4. The apparent affinity constant for the binding reaction, defined as
n/Kdiss, resulted to be on the order of 106 M−1 for both titrations. This value is comparable
to those tabulated for several well established DNA stains and DNA-binding drugs [58].
The fairly low value retrieved for n, corresponding to a binding length of four base pairs,
reasonably reflects the bulkiness of 1.
Table 4. Fitting parameters obtained by interpolation of the experimental binding isotherms of
Figure 6 with the independent binding site model, Equation (1).
Solvent Kdiss (M) n (ligands/bp) F0 (a.u.) δF (µM−1)
DMSO 0.69 ± 0.32 0.26 ± 0.05 2.07 ± 0.03 −0.098 ± 0.004
DMF 0.87 ± 0.39 0.29 ± 0.05 1.19 ± 0.02 −0.057 ± 0.005
2.2.4. Powder X-ray Diffraction Studies
Powder X-ray diffraction qualitative analysis revealed the reproducibility of the syn-
thetic path proposed for 1, not only at the molecular level, but also in the solid state: indeed,
the precipitate, recovered from the reaction medium in the form of microcrystalline pow-
ders, does show the same PXRD pattern (Figure S7). Unfortunately, attempts to retrieve the
unit cell parameters as the first step to undertake a crystal structure determination from
PXRD invariably failed, irrespective of the software used. Incidentally, due to the already
mentioned low solubility of 1 in different organic solvents, all the efforts carried out to
recrystallize it in the form of single crystals suitable for single-crystal X-ray diffraction were
not successful.
2.3. Coordination with DMSO and NMI
Although many zinc(II) coordination compounds are stable in a tetrahedral geometry,
some five-coordinated complexes have been reported in recent years [60–62]. One notable
example is provided by DMSO coordination [63]. As 1 is optimally soluble in this organic
solvent, we investigated the proneness of DMSO to act as extra ligand in the coordination
sphere of 1. Detailed synthetic procedures are given in the Supplementary Materials
section.
DMSO coordination to form [Zn2(µ-O)2(BMIP)2(DMSO)], 2, was indeed observed by
solid state IR spectroscopy. The band positions are listed in Table 1. The DMSO diagnostic
bands at 1031 (methyl rocking) and 961 cm−1 (S=O vibration) were identified, as shown in
Figure 7a. The red-shifted position of the latter band (the S=O vibration for free DMSO
falls at 1054 cm−1) suggests that DMSO binds to the metal center through the oxygen atom.
This is further confirmed by the presence of a band at 435 cm−1, attributed to Zn-ODMSO
stretching [64], as shown in Figure 7b. BMIP coordination is minimally affected by DMSO
binding. Indeed, its characteristic carbonyl band is observed at 1520 cm−1, not shifted
with respect to the tetra-coordinated complex, while the low frequency peak at 507 cm−1
ascribable to Zn-OBMIP stretching is only slightly blue-shifted to 510 cm−1.
DMSO coordination is also unravelled by solution NMR. The DMSO-characteristic
methyl signal at 2.58 ppm is identified in the 1H-NMR spectrum, along with an unmodified
BMIP aromatic pattern and the tautomeric equilibrium, see Supplementary Materials
Figure S8. The [Zn2(µ-O)2(BMIP)2(DMSO)] stoichiometry was confirmed by combined
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thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The TGA
profile shows that species 2 decomposes in two subsequent steps (see Supplementary
Materials Figure S9). The first one, occurring at 184 ◦C, is compatible with the removal
of the DMSO molecule (experimental mass loss: 7.92%, theoretical: 7.70%), and coincides
with an endothermic event detected by means of DSC. The second step, which starts at
310 ◦C and ends up with a 37.78% mass loss, corresponds to decomposition of 1. The
DSC/TGA of 1 is shown in Supplementary Materials Figure S10. Indeed, after DMSO
loss, the DSC and TGA curves of 2 follow the same trend observed for compound 1.
Although the high temperature required for DMSO ablation denotes the high stability of
the DMSO complex, the similar trend of the DSC/TGA curves measured for 1 and 2 at high
temperature suggests that DMSO ligation should be reversible. Accordingly, by heating
2 at 100 ◦C for 3 h under vacuum, 1 was reobtained in quantitative yield (Scheme 3), as
testified by IR spectroscopy.
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In conclusion, the above analyses demonstrate the ability of 1 to tune the zinc(II)
coordination geometry in the presence of electron donors. This ability might provide a
means for zinc(II) coordination with DNA nucleosides, as witnessed by the results exposed
in Section 2.2.3. The next step towards characterization of the binding mode of 1 to DNA
was to attempt coordination with N-methyl-imidazole (NMI), a widely used DNA mimic.
Namely, 1 was initially suspended overnight under stirring in NMI, filtered, washed
thoroughly to remove NMI residuals, and dissolved in CD2Cl2. Formation of [Zn2(µ-
O)2(BMIP)2(NMI)], 3, was evidenced by solution 1H-NMR, namely by the appearance of
the diagnostic N-Me signal at 3.71 ppm, as shown in Supplementary Materials Figure S11.
Coordinated NMI aromatic protons were spotted as broad signals at 7.56 ppm, 7.07 ppm
and 6.95 ppm, notably downfielded compared to the free molecule. The experiment was
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repeated starting from 2. In this instance, displacement of DMSO by NMI was observed.
Indeed, the 1H-NMR spectrum was characterized by the disappearance of the signal
at 2.58 ppm diagnostic of DMSO with concomitant appearance of the above-described
features signalling NMI complexation. Finally, NMI complexation was afforded in CH2Cl2,
adding the DNA mimic only in low amount (10 % v/v).
The infrared spectra of 3, see Figure 7, show two intense absorption bands at 1285 cm−1
and 1421 cm−1, attributed to the C–N and C=N ring stretching vibrations of NMI, respec-
tively. Furthermore, when 2 is used as the starting compound, the bands characteristic of
DMSO complexation (1031 cm−1, 961 cm−1 and 435 cm−1, vide supra) disappear.
The thermal behaviour of 3 was investigated by simultaneous DSC/TGA. The TGA
trace shows that 3 decomposes in two steps (Supplementary Materials Figure S12). The first
one, occurring at ≈ 220 ◦C, corresponds to removal of one NMI mole per mole of complex
(experimental mass loss: 8.14%, theoretical: 8.0%), in agreement with the endothermic
broad peak located at 253 ◦C (DSC). The second step occurs in the >360 ◦C temperature
range, with a mass loss of 43%, and corresponds to an endothermic decomposition process.
After loss of NMI, the DSC/TGA curve of 3 is very similar to that of 1.
Full coordination reversibility was also observed in this case, leading to quantitative
recovery of compound 1 after 3 h of vacuum heating at 180 ◦C (Scheme 3).
3. Materials and Methods
3.1. Chemicals and Samples Preparation
All the chemicals were purchased from commercial suppliers and used as received.
All reactions involving air- and/or moisture-sensitive materials were carried out under
inert atmosphere, using a standard Schlenk-line technique. Where specified, reactions were
monitored by thin layer chromatography (TLC), using ready-made ALUGRAM Xtra SIL
G/UV254 (0.2 mm thick layer, Macherey-Nagel). Spots were observed under a UV lamp
(365 nm and/or 254 nm). Gravimetric column chromatography was performed using silica
gel as stationary phase (0.63–2 µm particle size).
The samples in aqueous environment exploited in the electronic-state transition spec-
troscopy characterization and in the spectrophotometric titration experiments were derived
by highly concentrated stocks of 1 preliminarily solubilized in water-miscible organic
solvents, namely DMSO and DMF. Indeed, due to the very scarce water solubility of 1,
attempts to obtain clear water solutions by directly pouring powdered 1 in buffer failed, in
spite of heating, sonication or overnight stirring. First, the solvent rearrangement dynamics
(i.e., progressive detachment of the organic solvent and hydration) were monitored over
time by means of UV-Vis spectroscopy (see Figure 4 in the Results section). As these studies
revealed rather slow re-equilibration (roughly 5 h were needed to complete the process)
and progressive aggregation/precipitation of the hydrated compound, the samples used
for the titration experiments were kept under continuous stirring for 72 h by means of
a mechanic stirrer prior to acquisition of the fluorescence spectra. While preparing the
solutions, the DNA concentration in each sample was measured by acquisition of the
UV-spectrum prior to ligand addition. Namely, the tabulated molar extinction coefficient
value ε(260 nm) = 13,200 M−1cm−1 was used to derive the molarity in base pairs [58].
After this measurement, a nominal volume of 20 µL of ligand stock in either DMSO or
DMF was added to 3 mL of DNA solution in PBS by means of a micro-pipette (Brand).
The absorption spectrum in the 300–500 nm spectral region was acquired readily after,
when re-equilibration was still negligible. The absorption at 395 nm was then used to
perform ex-post correction of the fluorescence data with respect to fluctuations in the ligand
concentration owing to the pipette limited precision (≈2% according to the supplier).
3.2. Spectroscopy Experiments
IR spectra were acquired by the ATR method with a Nicolet iS10 instrument, over
the range 4000–600 cm−1. FTIR measurements in external reflection mode (FTIR-ER) were
carried out with an Alpha Bruker FTIR portable spectrophotometer, equipped with a DTGS
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detector. Spectra were collected between 800 cm−1 and 375 cm−1, with 4 cm−1 resolution
and 200 scans. The background was periodically acquired using a flat gold mirror. In the
following, intensities are denoted as: vs = very strong, s = strong, m = medium, w = weak
and vw = very weak. 1H and 13C(APT) solution NMR spectra were recorded on a Bruker
Avance I 400 MHz spectrometer. 1H and 13C data are reported as follows: chemical shifts
(in ppm and referenced to internal TMS), integration, multiplicity (s = singlet, d = doublet,
t = triplet, q = quartet, m = multiplet), and coupling constants (in Hz). Deuterated solvent
for NMR measurements, CD2Cl2, was used as received from Eurisotope. Fluorescence
spectra were acquired on a PTI Fluorescence Master System fluorimeter. The spectra
were automatically corrected with respect to the lamp spectral radiance and detector
quantum efficiency by exploiting a feature of the acquisition software, Felix 2000. The
values of fluorescence quantum yield were assessed by comparison to a tabulated standard,
namely dimethyl-POPOP dissolved in cyclohexane, Φfluo = 0.95 [65], and were corrected
with respect to solvent refractive index. HRMS spectra were recorded on MALDI Tof-
Tof Autoflex III instrument. Elemental composition analyses were performed with a
Perkin Elmer CHN Analyser 2400 Series II instrument. TGA and DSC were performed
simultaneously with a Netzsch STA 409 PC Luxx instrument (temp. range RT-600 ◦C, rate of
10 ◦C min−1, N2 atmosphere). Gas chromatography-mass spectrometry. UV-Vis absorption
spectra were recorded by means of a Perkin Elmer Lambda 2 spectrophotometer.
3.3. Powder X-ray Diffraction
Powder X-ray diffraction qualitative measurements were carried out in the 3–35◦
2θ range with steps of 0.02◦ and time per step of 1 s using a Bruker AXS D8 Advance
vertical-scan θ:θ diffractometer, equipped with a sealed X-ray tube (Cu Kα, λ = 1.5418 Å), a
Bruker Lynxeye linear position-sensitive detector, a Ni filter in the diffracted beam and the
following optical components: primary beam Soller slits (2.5◦), fixed divergence slit (0.5◦),
antiscatter slit (8 mm). The generator operated at 40 kV and 40 mA. Powdered samples
(~50 mg) of 1 were deposited in the cavity of an aluminum sample-holder 0.2 mm deep.
All the samples used for the spectroscopic characterization were preliminary checked by
elemental analysis and PXRD.
3.4. Synthesis of 1-methyl-5-methoxyindole
This compound was synthetized according to the procedure reported in the literature [66].
3.5. Synthesis of BMIP
This compound was synthetized according to the procedure reported in the literature [38].
3.6. Synthesis of [Zn2(µ-O)2(BMIP)2]
In a Schlenk tube BMIP (100 mg, 0.257 mmol, 1.1 eq.) was mixed with 2-methoxyethanol
(5 mL) and heated to 90 ◦C to allow complete dissolution while stirring. Zn(ClO4)2·6H2O
(86.9 mg, 0.233 mmol, 1 eq.) was added and the solution turned to a transparent dark red
color. Triethylamine (1 mL) was slowly added dropwise: modest precipitation of a dark
yellow solid was noted. The reaction mixture was then vigorously stirred and refluxed for
6 h, then slowly allowed to cool to room temperature. The crude product was filtered on
a glass filter funnel and subsequently washed with 2-methoxyethanol, distilled water and
methanol. The isolated yellow solid was transferred into a vial and dried under vacuum at
120 ◦C for 3 h.
1H-NMR(CD2Cl2), δ(ppm): 7.98 (diketo, s, 4H); 7.73 (diketo, d, 4H, 4J = 2.35 Hz); 7.70
(enol, s, 4H); 7.68 (enol, d, 4H, 4J = 2.34 Hz); 7.22 (enol, d, 4H, 3J = 8.84 Hz); 7.16 (diketo,
d, 4H, 3J = 8.85 Hz); 6.88 (enol, d, 4H, 4J = 2.34 Hz, 3J = 8.85 Hz); 6.82 (diketo, d, 4H,
4J = 2.34 Hz, 3J = 8.85 Hz); 6.40 (enol, s, 2H); 4.19 (diketo, s, 4H); 3.83 (enol, s, 12H), 3.76
(diketo, s, 12H); 3.75 (diketo, s, 12H). 13C-NMR(CD2Cl2), δ(ppm): 188.0 (CO); 156.6 (C);
138.1 (CH); 132.9 (C), 132.5 (C); 127.3 (C); 113.4 (CH); 110.6 (CH); 10.6 (CH); 55.6 (OCH3);
55.3 (CH2); 33.7 (NCH3). IR (ATR) ῦ(cm−1): 3010 (vw); 2927 (vw); 2832 (vw); 1580 (w); 1520
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(vs); 1480 v(s); 1407, (s); 1379 (s); 1362 (s); 1290 (m); 1267 (m); 1212 (vs); 1142 (m); 1097
(vs);974 (m); 896 (m); 859(m); 801 (s); 773 (vs); 695 (vs); 507 (m). HMRS-(TOF-ESI): m/z
calcd. for C46H44N4O10Zn2Na: 966.6696 [M + Na]+; found: 966.6675 [M + Na]+. Elem.
Anal. Calcd. for C46H44N4O10Zn2 (FW = 943.68 g/mol): C = 58.55%, H = 4.70%, N = 5.94%;
found: C = 59.18%, H = 4.95%, N = 6.24%.
3.7. Synthesis of [Zn2(µ-O)2(BMIP)2(DMSO)]—Direct Method
In a Schlenk tube, BMIP (101.5 mg, 0.26 mmol, 1.1 eq.) was mixed with DMSO
(2 mL) and heated to 40 ◦C to allow complete dissolution while stirring. Zn(ClO4)2·6H2O
(88.07 mg, 0.236 mmol, 1 eq.) was added and the solution turned to a transparent dark
orange color. Triethylamine (1 mL) was slowly added dropwise: modest precipitation
of a light-yellow solid was noted. The reaction mixture was then vigorously stirred and
refluxed for 4 h, then slowly allowed to cool to room temperature. The crude product was
filtered on a glass filter funnel and subsequently washed with DMSO, distilled water and
methanol in the end. The isolated yellow solid was transferred into a vial and dried under
vacuum at 90 ◦C for 3 h.
3.8. Synthesis of [Zn2(µ-O)2(BMIP)2(DMSO)]—Indirect Method
In a 10 mL vial [Zn2(µ-O)2(BMIP)2] (20 mg, 0.02 mmol) was dissolved in DMSO
(1.0 mL) and stirred for 12 h at room temperature. A yellow precipitate formed: it was
filtered on a small Hirsch filter funnel and washed with diethyl ether (5 × 5 mL). The
isolated yellow solid was transferred into a vial and dried under vacuum at 90 ◦C for 3 h.
1H-NMR(CD2Cl2), δ(ppm): 8.00 (diketo, s, 4H); 7.85 (diketo, d, 4H, 5J = 2.35 Hz); 7.81
(enol, s, 4H); 7.80 (enol, d, 4H, 5J = 2.54 Hz); 7.33 (enol, d, 4H, 3J = 8.90 Hz); 7.27 (diketo,
d, 4H, 3J = 8.85 Hz); 6.99 (enol, dd, 4H, 5J = 2.34 Hz, 3J = 8.85 Hz); 6.94 (diketo, dd, 4H,
5J = 2.34 Hz, 3J = 8.85 Hz); 6.69 (enol, s, 2H); 4.31 (diketo, s, 4H); 3.87 (enol, s, 12H), 3.85
(diketo, s, 12H); 2.58 (DMSO, s, 6H). IR (ATR) ῦ(cm−1): 3010 (vw); 2927 (vw); 2832 (vw);
1580 (w); 1520 (vs); 1475 v(s); 1408, (s); 1382 (s); 1365 (vs); 1293 (s); 1267 (s); 1208 (vs);
1126 (vs); 1108 (s); 1095 (vs); 1131 (m); 1008 (m); 970 (m); 963 (m); 894 (m); 860 (m); 808 (vs);
692 (vs); 510 (m); 434 (m). Elem. Anal. Calcd. for C48H50N4O11Zn2 (FW = 1021.81 g/mol):
C =56.42%, H = 4.93%, N = 5.48%; found: C = 56.05%, H = 5.01%, N = 5.84%. The IR
spectrum is reported in Supplementary Materials Figure S13.
3.9. Synthesis of [Zn2(µ-O)2(BMIP)2(NMI)]
In a 10 mL vial [Zn2(µ-O)2(BMIP)2] (20 mg, 0.02 mmol) was dissolved in
1-methylimidazole (1.0 mL) and stirred for 12 h at room temperature. A yellow pre-
cipitate formed: it was filtered on a small Hirsch filter funnel and washed with diethyl
ether (5 × 5 mL). The isolated yellow solid was transferred into a vial and dried under
vacuum at 100 ◦C for 4 h.
3.10. Synthesis of [Zn2(µ-O)2(BMIP)2(NMI)]—Ligand Exchange
In a 10 mL Schlenk tube [Zn2(µ-O)2(BMIP)2(DMSO)] (51.7 mg, 0.05 mmol) was dis-
solved in CH2Cl2 (4 mL) and then 1-methylimidazole (400 µL) was added. The solution
was stirred for 12 hrs at room temperature. A yellow precipitate formed: it was filtered on
a small Hirsch filter funnel and washed with diethyl ether (5 × 5 mL). The isolated yellow
solid was transferred into a vial and dried under vacuum at 100 ◦C for 4 h.
1H-NMR(CD2Cl2), δ(ppm): 8.10 (diketo, s, 4H); 7.85 (diketo, d, 4H, 5J = 2.35 Hz);
7.81 (enol, s, 4H); 7.80 (enol, d, 4H, 5J = 2.54 Hz); 7.56 (NMI, sb, 1H); 7.34 (enol, d,
4H, 3J = 8.88 Hz); 7.28 (diketo, d, 4H, 3J = 8.89 Hz); 7.07 (NMI, sb, 1H); 6.99 (enol, dd,
4H, 5J = 2.50 Hz, 3J = 8.89 Hz); 6.95 (NMI, sb, 1H); 6.94 (diketo, dd, 4H, 5J = 2.35 Hz,
3J = 8.88 Hz); 6.51 (enol, s, 2H); 4.31 (diketo, s, 4H); 3.95 (enol, s, 12H); 3.88 (enol, s, 12H);
3.87 (enol, s, 24H), 3.71 (NMI, s, 3H). IR (ATR) ῦ(cm−1): 2992 (vw); 2932 (w); 2829 (w);
1580 (w); 1520 (vs); 1474 (vs); 1422, (m); 1418 (m); 1408 (s); 1385 (m); 1364 (s); 1211 (vs);
1095 (s); 1034 (m); 973 (m); 1131 (m); 948 (w); 842 (w); 771 (s); 694 (s); 860 (m); 518 (m).
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Elem. Anal. Calcd. for C50H50N6O10Zn2 (FW = 1025.78 g/mol): C = 58.54%, H = 4.91%,
N = 8.19%; found: C = 59.01%, H = 4.95%, N = 8.30%. The IR spectrum is reported in
Supplementary Materials Figure S14.
4. Conclusions
[Zn2(µ-O)2(BMIP)2] (BMIP = 1,3-bis(5-methoxy-1-methyl-1H-indol-3-yl)propane-1,3-
dione), 1, a novel, highly stable zinc(II) µ-oxo-bridged dimeric complex, was synthesized
in quantitative yield according to original procedures. Its complex keto-enolic tautomerism
was elucidated by combining NMR, IR and UV-Vis spectroscopy. The ability of the zinc(II)
ion to change coordination number in the presence of highly electrophilic moieties when
caged within the ligand dimer was unravelled, and the coordination with the organic
solvent DMSO and with the base scaffold NMI was studied in detail. Finally, high affinity
of the compound for DNA in pseudo-physiologic environment was demonstrated by
means of fluorescence spectroscopy. The chemico-physical parameters characterizing the
binding were estimated by fitting the binding isotherms according to the independent
binding site model. In conclusion, 1 exhibits the essential properties to be considered as
a starting scaffold compound for the development of a novel family of Zn-based DNA-
targeting metallodrugs. Further efforts should be devoted to improve water solubility of
these drug substances, which is actually very poor, in order to increase their bioavailability.
Presently, attempts in this sense are being undertaken in our laboratories. Namely, we are
adopting the strategy of modifying the substitutions on the nitrogen atoms of the indole
rings of the ligand inserting polar groups. Other modifications will be explored on the
benzene rings.
Supplementary Materials: The following materials are available online at https://www.mdpi.com/
article/10.3390/ph14080760/s1, Figure S1: 1H-NMR spectrum of 1, Figure S2: 13C-NMR spectrum of
1, Figure S3: IR spectrum of 1, Figure S4: Fluorescence excitation spectra of 1 in selected solvents,
Figure S5: Reconstructed fluorescence emission spectra of the diketo tautomers of 1 in selected
solvents, Figure S6: Absorption and fluorescence spectra of 1 in water and bound to DNA, Figure S7:
PRXD pattern, Figure S8: 1H-NMR spectrum of 2, Figure S9: DSC/TGA trace of 2, Figure S10:
DSC/TGA trace of 1, Figure S11: 1H-NMR spectrum of 3, Figure S12: DSC/TGA trace of 3, Figure S13:
IR spectrum of 2, Figure S14: IR spectrum of 3.
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45. Prochowicz, D.; Sokołowski, K.; Lewiński, J. Zinc hydroxides and oxides supported by organic ligands: Synthesis and structural
diversity. Coord. Chem. Rev. 2014, 270–271, 112–126. [CrossRef]
46. Ruqia, B.; Nam, K.M.; Lee, H.; Lee, G.; Choi, S.I. Facile synthesis of highly crystalline ZnO nanorods with controlled aspect ratios
and their optical properties. CrystEngComm 2017, 19, 1454–1458. [CrossRef]
47. Adati, R.D.; Lima, S.A.M.; Davolos, M.R.; Jafelicci, M. A new β-diketone complex with high color purity. J. Alloy. Compd. 2006,
418, 222–225. [CrossRef]
48. Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds, 3rd ed.; Wiley Interscience: New York, NY,
USA, 1969.
49. Nardo, L.; Maspero, A.; Selva, M.; Bondani, M.; Palmisano, G.; Ferrari, E.; Saladini, M. Excited-state dynamics of bis-
dehydroxycourcumin carboxylic acid, a water-soluble derivative of the photosensitizer curcumin. J. Phys. Chem. A 2012,
116, 9321–9330. [CrossRef] [PubMed]
50. Nardo, L.; Maspero, A.; Penoni, A.; Palmisano, G.; Ferrari, E.; Saladini, M. Excited state dynamics of bis-dehydroxycurcumin
tert-butyl ester, a diketo-shifted derivative of the photosensitizer curcumin. PLoS ONE 2017, 12, e0175225. [CrossRef]
51. Ferrari, E.; Pignedoli, F.; Imbrano, C.; Marverti, G.; Basile, V.; Venturi, E.; Saladini, M. Newly synthesized curcumin derivatives:
Crosstalk between chemico-physical properties and biological activity. J. Med. Chem. 2011, 54, 8066–8077. [CrossRef]
52. Chignell, C.F.; Bilskj, P.; Reszka, K.J.; Motten, A.G.; Sik, R.H.; Dahl, T.A. Spectral and photochemical properties of curcumin.
Photochem. Photobiol. 1994, 59, 295–302. [CrossRef]
53. Nardo, L.; Paderno, R.; Andreoni, A.; Masson, M.; Haukvik, T.; Tonnesen, H.H. Role of H-bond formation in the photoreactivity
of curcumin. Spectroscopy 2008, 22, 187–198. [CrossRef]
54. Nardo, L.; Andreoni, A.; Bondani, M.; Masson, M.; Tonnesen, H.H. Studies on curcumin and curcuminoids. XXXIV. Photophysical
properties of a symmetrical, non-substituted curcumin analogue. J. Photochem. Photobiol. B Biol. 2009, 97, 77–86. [CrossRef]
55. Nardo, L.; Andreoni, A.; Masson, M.; Tonnesen, H.H. Photophysical properties of bis-demethoxy-curcumin. J. Fluoresc. 2011,
21, 627–635. [CrossRef] [PubMed]
56. Nardo, L.; Andreoni, A.; Bondani, M.; Masson, M.; Haukvik, T.; Tonnesen, H.H. Photophysical properties of dimethoxycurcumin
and bis-dehydroxycurcumin. J. Fluoresc. 2012, 22, 597–608. [CrossRef] [PubMed]
Pharmaceuticals 2021, 14, 760 17 of 17
57. Lamperti, M.; Maspero, A.; Tønnesen, H.H.; Bondani, M.; Nardo, L. Elucidation of the relationships between H-bonding patterns
and excited state dynamics in Cyclovalone. Molecules 2014, 19, 13282–13304. [CrossRef]
58. Nardo, L.; Bondani, M.; Andreoni, A. Discrimination of the binding-mode of DNA-ligands by single photon timing. Spectroscopy
2009, 23, 11–28. [CrossRef]
59. Giani, A.M.; Lamperti, M.; Maspero, A.; Cimino, A.; Negri, R.; Giovenzana, G.B.; Palmisano, G.; Nardo, L. Fluorescence studies
on 2-(het)aryl perimidine derivatives. J. Lumin. 2016, 179, 384–392. [CrossRef]
60. Franks, M.; Gadzhieva, A.; Ghandhi, L.; Murrell, D.; Blake, A.J.; Davies, E.S.; Lewis, W.; Moro, F.; McMaster, J.; Schröder, M. Five
coordinate M (II)-diphenolate [M= Zn (II), Ni (II), and Cu (II)] Schiff base complexes exhibiting metal-and ligand-based redox
chemistry. Inorg. Chem. 2013, 52, 660–670. [CrossRef]
61. Song, X.W.; Gao, X.J.; Liu, H.X.; Chen, H.; Chen, C.N. Synthesis and characterization of a supramolecular assembly based on a
pyridyl-functionalized [FeFe]-hydrogenase mimic and zinc tetraphenylporphyrin. Inorg. Chem. Commun. 2016, 70, 1–3. [CrossRef]
62. Che, W.; Yu, T.; Jin, D.; Ren, X.; Zhu, D.; Su, Z.; Bryce, M.R. A simple oxazoline as fluorescent sensor for Zn2+ in aqueous media.
Inorg. Chem. Commun. 2016, 69, 89–93. [CrossRef]
63. Liu, Z.-Q.; Ng, Y.M.; Tiong, P.J.; Abu Talip, R.A.; Jasin, N.; Jong, V.Y.M.; Tay, M.G. Five-Coordinate Zinc(II) Complex: Synthesis,
Characterization, Molecular Structure, and Antibacterial Activities of Bis-[(E)-2-hydroxy-N’-{1-(4-methoxyphenyl)ethylidene}benzohydrazido]dimethylsulfoxidezinc(II)
Complex. Int. J. Inorg. Chem. 2017, 2017, 7520640. [CrossRef]
64. Evans, I.P.; Spencer, A.; Wilkinson, G. Dichlorotetrakis(dimethyl sulphoxide)ruthenium(II) and its use as a source material for
some new ruthenium(II) complexes. J. Chem. Soc. Dalton Trans. 1973, 2, 204–209. [CrossRef]
65. Berlman, I.B. Handbook of Fluorescence Spectra of Aromatic Molecules; Academic Press: New York, NY, USA, 1971.
66. Rochette, E.; Desrosiers, V.; Soltani, Y.; Fontaine, F.G. Isodesmic C-H Borylation: Perspectives and Proof of Concept of Transfer
Borylation Catalysis. J. Am. Chem. Soc. 2019, 141, 12305–12311. [CrossRef] [PubMed]
